Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Aug 11;105(8):933–942. doi: 10.1111/cas.12459

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Fig. 5 — Interleukin (IL)-17A and IL-22 inhibited IL-12-inducing interferon (IFN)-γ-producing cells in peripheral blood mononuclear cells (PBMCs). (a) & (b) PBMCs from healthy donors or AML patients were activated with Th1 polarizing cytokines (IL-12, 10 ng/mL; anti-CD3 antibody, 1.5 μg/mL) with or without IL-17A (10 ng/mL) and IL-22 (10 ng/mL) for 12 days. Cells were subsequently stimulated with phorbol 12-myristate13-acetate (PMA) and ionomycin in the presence of brefeldin A, stained for intercellular IFN-γ, and analyzed by flow cytometry. A representative dot plot analysis showing percentage of IFN-γ-positive cells within gated CD3⁺CD4⁺ (CD3⁺CD8^-) population. Results are expressed as mean ± SEM representing five independent experiments from different healthy donors or AML patients. (c) PBMCs from healthy donors or AML patients were stimulated with Th1 polarizing cytokines with or without IL-17A and IL-22 for 6 days, and supernatants were determined for IFN-γ by ELISA.